10-Q: Enveric Biosciences Q3 2025: Liquidity Concerns Persist

Enveric Biosciences reports continued losses and substantial doubt about its ability to continue as a going concern, despite recent capital raises and Nasdaq compliance.

Summary

• The company incurred an accumulated deficit of $112,652,321 as of September 30, 2025, with further losses anticipated.
• Net loss for the nine months ended September 30, 2025, was $(6,577,816), compared to $(6,420,341) for the same period in 2024.
• Operating cash outflows for the nine months ended September 30, 2025, totaled $(6,356,680).
• Cash on hand was $3,757,594 as of September 30, 2025, an increase from $2,241,026 at December 31, 2024.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year due to insufficient cash to meet operating needs.
• The company successfully regained compliance with Nasdaq's minimum stockholders equity and bid price requirements following recent capital raises and a 1-for-12 reverse stock split.
• Key capital raising activities included a public offering in January 2025 ($4,244,467 net proceeds), an inducement warrant transaction in September 2025 ($2,218,873 gross proceeds), and an At-The-Market (ATM) offering ($1,636,799 net cash proceeds as of September 30, 2025).
• The primary focus remains on developing its lead candidate, EB-003 (EVM301 Series), for psychiatric and neurological disorders, with plans to advance it into preclinical studies for a future IND filing.
• The EVM201 Series program was out-licensed to MycoMedica Life Sciences in Q4 2024, with potential for up to $62 million in milestone payments and tiered single-digit royalties.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues and has an accumulated deficit, raising substantial doubt about its going concern status. While it has successfully raised capital and regained Nasdaq compliance, these are temporary fixes without a clear path to profitability. The R&D focus on EB-003 and out-licensing are positive strategic moves, but the financial health remains very weak.

Positives

• Regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders equity) with $3,456,176 in stockholders equity as of September 30, 2025.
• Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price) after a 1-for-12 reverse stock split on October 23, 2025.
• Successfully raised significant capital through a public offering ($4,244,467 net), an inducement warrant transaction ($2,218,873 gross), and an ATM Agreement ($1,636,799 net) during the nine months ended September 30, 2025.
• Cash balance increased to $3,757,594 as of September 30, 2025, from $2,241,026 at December 31, 2024.
• Working capital improved to $3,259,655 as of September 30, 2025, from $1,244,848 at December 31, 2024.
• Out-licensed EVM201 Series program to MycoMedica Life Sciences, with potential for up to $62 million in development and sales milestone payments and tiered single-digit royalties.
• Research and development expenses decreased by 50% to $402,417 for the three months ended September 30, 2025, compared to $802,717 for the same period in 2024, primarily due to reduced CRO costs, salaries, and research costs.

Negatives

• Incurred an accumulated deficit of $112,652,321 as of September 30, 2025, indicating ongoing unprofitability.
• Reported a net loss of $(1,873,669) for the three months ended September 30, 2025, and $(6,577,816) for the nine months ended September 30, 2025.
• Operating cash outflows were $(6,356,680) for the nine months ended September 30, 2025.
• The company has not generated any revenue since inception.
• Current cash on hand ($3,757,594) is insufficient to satisfy operating cash needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• General and administrative expenses increased by 20% to $1,431,157 for the three months ended September 30, 2025, compared to $1,195,661 for the prior year period, primarily due to increases in marketing, Delaware Franchise Tax, and legal expenses.
• Research and development expenses increased by 29% to $2,408,839 for the nine months ended September 30, 2025, compared to $1,873,873 for the prior year period, mainly due to a significant increase in consulting fees.
• Identified material weaknesses in internal controls over financial reporting as of December 31, 2024, due to inadequate segregation of duties.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements due to incurred losses and insufficient cash on hand.
• Inability to raise adequate additional financing on acceptable terms, or at all, which may require further cost-cutting measures, including delaying or discontinuing certain operating activities.
• Exposure to changes in the exchange rates of the Canadian dollar and Australian dollar against the United States dollar.
• Risks associated with the development and regulatory approval of product candidates (EB-003, EVM401 Series), including the selection, timing, duration, and design of prospective studies.
• Reliance on third-party collaborations (e.g., MycoMedica Life Sciences) for development, manufacturing, and commercialization of out-licensed programs.
• Material weaknesses in internal controls over financial reporting due to inadequate segregation of duties, which could adversely affect the ability to record, process, summarize, and report financial information.
• The company has not generated revenue since inception and anticipates further losses.

Future Outlook

The company intends to broaden its pipeline with additional non-hallucinogenic molecules (EVM401 Series) while primarily focusing on developing its lead asset EB-003 in the EVM301 Series. The next step is to advance EB-003 into formal preclinical development studies to support a future Investigational New Drug (IND) filing, aiming to initiate first-in-human studies to assess safety and tolerability, including non-hallucinogenic properties, followed by clinical trials for depression or other neuropsychiatric disorders. The company plans to submit IND applications and eventually new drug applications (NDAs) to the U.S. FDA and other regulatory agencies. Management plans to alleviate going concern issues by raising additional working capital through public or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined cash spending.

Management Comments

• "Our belief that EB-003 is the first known compound to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience."
• "Our intention to broaden our pipeline with additional non-hallucinogenic molecules with the unveiling of the EVM401 Series."
• "Our belief that the EVM401 Series will strengthen our ability to target addiction and neuropsychiatric disorders for patients with limited options."
• "Our intention to pursue the EVM401 Series, but primarily focus on developing our lead asset EB-003 in the EVM301 Series."
• "Our belief that factors exist that raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements."
• "Management's plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined cash spending."
• "Our belief that adequate additional financing may not be available to the Company on acceptable terms, or at all."
• "Our belief that should the Company be unable to raise sufficient additional capital, the Company may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities."
• "Our belief that the outcome of such legal proceedings that the Company may periodically be engaged in the normal course of business will not have a significant adverse effect on the Company's financial position, results of operations or cash flows."
• "Our belief that our lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient."
• "Our plan to submit filings including Investigational New Drug (IND) applications and, eventually, new drug applications (NDAs) to seek approval with the U.S. Food and Drug Administration (FDA) and with responsible regulatory agencies in other jurisdictions, in connection with our product candidates."
• "Our belief that we have regained compliance with Nasdaq Listing Rule 5550(b)(1)."

Industry Context

The company operates in the biotechnology sector, specifically focusing on neuroplastogenic therapeutics for psychiatric and neurological disorders. This is a growing area of research, particularly for non-hallucinogenic compounds that promote neuroplasticity, addressing a significant unmet medical need. The out-licensing of the EVM201 series to MycoMedica Life Sciences indicates a strategy to monetize earlier-stage assets while focusing internal resources on lead candidates like EB-003, a common practice in the biotech industry to manage R&D costs and diversify risk. The development of compounds targeting 5-HT2A and 5-HT1B receptors is a specific approach within neuropsychiatric drug discovery.

Corporate Governance

Legal Proceedings

• The Company is periodically involved in legal proceedings, legal actions, and claims arising in the normal course of business.
• Management believes that the outcome of such legal proceedings will not have a significant adverse effect on the Company's financial position, results of operations, or cash flows.
• No pending litigation is deemed to have a material adverse effect.

Related Party Transactions

• As of December 31, 2024, the Company had $232,891 due to related parties, which was reduced to $0 as of September 30, 2025.
• Board member Sheila DeWitt provided research and development services as an advisory consultant. The Company incurred $3,250 in service fees for the nine months ended September 30, 2025, which has been paid. For the nine months ended September 30, 2024, $132,000 was incurred.

Stakeholder Impact

• Shareholders: Experience dilution from recent and potential future equity raises (public offering, inducement warrants, ATM). Face risk of further share price volatility due to going concern issues and reverse stock splits. Potential for value creation exists if lead candidates succeed, but overall risk is high due to current financial state.
• Employees: Potential for cost-cutting measures, including delays or discontinuations of operating activities, if additional capital is not raised, which could impact employment.
• Creditors: Increased risk due to the "going concern" doubt, potentially affecting terms for future debt financing.
• Customers/Partners (MycoMedica, Aries, Restoration Biologics): Continued development of licensed products depends on the financial stability of both Enveric and its partners. Enveric's ability to meet its obligations under licensing agreements could be impacted by its financial health.

Next Steps

• Advance EB-003 into formal preclinical development studies.
• Support a future Investigational New Drug (IND) filing for EB-003.
• Initiate first-in-human studies for EB-003 to assess safety, tolerability, and non-hallucinogenic properties.
• Conduct clinical trials targeting the treatment of depression or other neuropsychiatric disorders for EB-003.
• Assemble a team of clinical experts and principal investigators for clinical research.
• Submit IND applications and eventually new drug applications (NDAs) to the U.S. FDA and other regulatory agencies.
• Pursue development of the EVM401 Series.
• Obtain stockholder approval for issuing underlying Inducement Warrant Shares upon exercise of the Inducement Warrants.
• File a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares within 10 days of entering into the Inducement Letters.
• Raise additional working capital through public or private equity or debt financings or other sources.
• Potentially undertake further cost-cutting measures, including delaying or discontinuing certain operating activities, if sufficient capital is not raised.
• Continue remediation efforts for material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company explicitly states "substantial doubt about the Company's ability to continue as a going concern" and has an accumulated deficit exceeding $112 million with no revenue generation since inception. While recent capital raises have provided some liquidity and Nasdaq compliance has been regained, these are temporary measures. The company remains highly dependent on future financing, which may not be available on acceptable terms. The material weakness in internal controls adds another layer of risk. Despite strategic focus on EB-003 and out-licensing, the fundamental financial instability and high burn rate make this a high-risk investment with significant downside potential. A seasoned investor would likely view the going concern warning as a critical red flag, suggesting an exit or avoidance of the stock.

Keywords

Biotechnology, Neuroplastogenic therapeutics, Psychiatric disorders, Neurological disorders, EB-003, EVM301 Series, EVM401 Series, Drug development, Preclinical studies, IND filing, Nasdaq compliance, Going concern, Capital raise, Warrants, Reverse stock split, SEC filing, 10-Q, Financial results, Biopharma